Pharmacometric Analysis of Zavegepant for Treatment of Migraine

被引：0
|
作者：
Comisar, C. [1 ]
Francis, J. [1 ]
Bhardwaj, R. [1 ]
Croop, R. [2 ]
Coric, V [3 ]
Bertz, R. [3 ]
机构：
[1] Certara, Princeton, NJ USA
[2] Pfizer Inc, New York, NY USA
[3] Biohaven Pharmaceut Inc, New Haven, CT USA
来源：
HEADACHE | 2023年 / 63卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
IO-09
引用
收藏
页码：153 / 154
页数：2
相关论文
共 50 条
  • [21] Intranasal Zavegepant is Effective and Well Tolerated for the Acute Treatment of Migraine: A Phase 2/3 Dose-Ranging Clinical trial
    Croop, Robert
    Madonia, Jennifer
    Conway, Charles
    Thiry, Alexandra
    Forshaw, Micaela
    Murphy, Abigail
    Jensen, Christopher
    Dubowchik, Gene
    Coric, Vlad
    Lipton, Richard
    NEUROLOGY, 2021, 96 (15)
  • [22] Long-term safety of zavegepant nasal spray for the acute treatment of migraine: A phase 2/3 open-label study
    Mullin, Kathleen
    Croop, Robert
    Mosher, Linda
    Fullerton, Terence
    Madonia, Jennifer
    Lipton, Richard B.
    CEPHALALGIA, 2024, 44 (08)
  • [23] A Knowledge Management Solution for Pharmacometric Analysis
    Fox, Robert
    Schmidt, Henning
    Al-Huniti, Nidal
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2016, 43 : S77 - S77
  • [24] Efficacy and Safety of Zavegepant Nasal Spray for the Acute Treatment of Migraine: Results of a Phase 3 Double-Blind, Randomized, Placebo Controlled Trial
    Mullin, Kathleen
    Croop, Robert
    Pavlovic, Jelena M.
    Mosher, Linda
    Smith, Timothy R.
    Madonia, Jennifer
    Lovegren, Meghan
    Coric, Vladimir
    Lipton, Richard B.
    CEPHALALGIA, 2022, 42 (1_SUPPL) : 126 - 127
  • [25] Efficacy and safety of zavegepant nasal spray for the acute treatment of migraine: Results of a phase 3 double-blind, randomized, placebo controlled trial
    Mullin, K.
    Croop, R.
    Pavlovic, J. M.
    Mosher, L.
    Smith, T. R.
    Madonia, J.
    Lovegren, M.
    Coric, V
    Lipton, R. B.
    HEADACHE, 2022, 62 : 128 - 129
  • [26] Efficacy and Safety of Zavegepant Nasal Spray for the Acute Treatment of Migraine: Results of a Phase 3 Double-Blind, Randomized, Placebo Controlled Trial
    Mullin, Kathleen
    Croop, Robert
    Pavlovic, Jelena
    Mosher, Linda
    Smith, Timothy
    Madonia, Jennifer
    Lovegren, Meghan
    Lipton, Richard
    NEUROLOGY, 2023, 100 (17)
  • [27] A Phase 2/3 Open-label, Long-term, Safety Trial of Zavegepant 10 mg Nasal Spray for the Acute Treatment of Migraine
    Croop, Robert
    Madonia, Jennifer
    Hould, Jennifer
    Mosher, Linda
    Lovegren, Meghan
    Lipton, Richard
    NEUROLOGY, 2023, 100 (17)
  • [28] Efficacy and Safety of Zavegepant Nasal Spray for the Acute Treatment of Migraine: Results of a Phase 3 Double-Blind, Randomized, Placebo Controlled Trial
    Mullin, K.
    Croop, R.
    Pavlovic, J.
    Mosher, L.
    Smith, T.
    Madonia, J.
    Lovegren, M.
    Coric, V.
    Lipton, R.
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [29] Efficacy of Zavegepant Nasal Spray for the Acute Treatment of Migraine Based on Triptan Treatment Experience: Pooled Results From 2 Randomized, Placebo- Controlled Clinical Trials
    Joshi, S.
    Smith, T.
    Pavlovic, J.
    Mullin, K.
    Croop, R.
    Mosher, L.
    Lovegren, M.
    Forshaw, M.
    Lipton, R.
    HEADACHE, 2023, 63 : 137 - 138
  • [30] Pharmacometric analysis of the effect of furosemide on suramin pharmacokinetics
    Piscitelli, SC
    Forrest, A
    Lush, RM
    Ryan, N
    Whitfield, LR
    Figg, WD
    PHARMACOTHERAPY, 1997, 17 (03): : 431 - 437
12345